Your session is about to expire
β Back to Search
Part 2: QTX3034 monotherapy dose-expansion for Solid Tumors
Study Summary
This trial aims to test if QTX3034 is safe to use alone or together with cetuximab.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check βYesβ for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are there any available vacancies for potential participants in this research study?
"The information provided on clinicaltrials.gov affirms the ongoing patient recruitment for this particular trial. The trial was initially listed on 2/5/2024 and last revised on the same date."
What is the current number of individuals receiving treatment within this specific clinical trial?
"Indeed, the details available on clinicaltrials.gov affirm that this trial is currently in the recruitment phase. Initial information about the clinical study was uploaded on February 5th, 2024, with the latest update made also on February 5th, 2024. The research aims to enroll a total of 250 participants from a single site."
What is the safety profile of Part 1b: QTX3034 in combination with cetuximab using dose-escalation for individuals undergoing treatment?
"When assessing the safety of Part 1b involving QTX3034 in combination with cetuximab through dose escalation, our team at Power rated it as a 1 on the scale. This Phase 1 trial has limited evidence supporting both safety and efficacy."
Share this study with friends
Copy Link
Messenger